Sino Biopharmaceutical (FRA:SMZ1) Total Stockholders Equity : €3,865 Mil (As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Sino Biopharmaceutical Total Stockholders Equity?

Sino Biopharmaceutical's Total Stockholders Equity for the quarter that ended in Jun. 2023 was €3,865 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Sino Biopharmaceutical's Book Value per Share for the quarter that ended in Jun. 2023 was €0.21. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Sino Biopharmaceutical's Debt-to-Equity for the quarter that ended in Jun. 2023 was 0.39.

Sino Biopharmaceutical Total Stockholders Equity Historical Data

The historical data trend for Sino Biopharmaceutical's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Total Stockholders Equity Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

1,918.29

2,105.14

4,208.88

4,027.88

3,913.77

Sino Biopharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															4,208.88	4,269.12	4,027.88	3,865.18	3,913.77

Sino Biopharmaceutical (FRA:SMZ1) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Sino Biopharmaceutical's Book Value per Share for the quarter that ended in Jun. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(3865.183	-	0)	/	18809.2
	=	0.21

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Sino Biopharmaceutical's Debt-to-Equity for the quarter that ended in Jun. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1356.228	+	132.923)	/	3865.183
	=	0.39

Sino Biopharmaceutical Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical (FRA:SMZ1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

SBHMY:USA SBMFF:USA 01177:Hong Kong SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (FRA:SMZ1) Headlines

No Headlines